Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Clinical Execution of Lead GeneTAC™ Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia Robust Research Pipeline of GeneTAC™ Candidates, with Promising New...
-
Topline Data from Phase 1 Trial Expected in the Second Half of 2022 DT-216 Granted FDA Fast Track Designation for Patients with Friedreich Ataxia CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE)...
-
Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTAC™ Small Molecules for the...
-
CARLSBAD, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that...
-
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon Topline Data from Phase 1 Trial Expected in the Second Half of 2022 CARLSBAD, Calif., Feb. 28, 2022 (GLOBE...
-
CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that...
-
CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that...
-
Clinical Initiation of Lead GeneTACTM Program for Friedreich Ataxia On-track for the First Half of 2022 CARLSBAD, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN),...
-
CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing small molecule treatments for degenerative genetic disorders, today...
-
Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 Leadership Team Strengthened with Appointment of Elizabeth Gordon,...